Ginkgo Bioworks Holdings, Inc.

Equities

DNA

US37611X1000

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:02 2024-05-22 pm EDT			5-day change	1st Jan Change
0.701 ^USD	-4.14%		-16.46%	-58.52%

May. 16	Ginkgo Bioworks Holdings Insider Bought Shares Worth $514,750, According to a Recent SEC Filing	MT
May. 15	BTIG Downgrades Ginkgo Bioworks Holdings to Sell From Neutral, Price Target is $0.50	MT

Ginkgo Bioworks Holdings, Inc. Updates Revenue Guidance for the Full Year 2024

May 09, 2024 at 05:30 pm EDT

Ginkgo Bioworks Holdings, Inc. updated revenue guidance for the full year 2024. Due to the changes in the company?s deal structure and focus on cost savings, the company now expects total revenue of $170 million to $190 million in 2024.

Latest news about Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings Insider Bought Shares Worth $514,750, According to a Recent SEC Filing	May. 16	MT
BTIG Downgrades Ginkgo Bioworks Holdings to Sell From Neutral, Price Target is $0.50	May. 15	MT
Morgan Stanley Trims Ginkgo Bioworks Price Target to $1 From $2, Maintains Equal Weight Rating	May. 15	MT
Ginkgo Bioworks Holdings Insider Bought Shares Worth $271,815, According to a Recent SEC Filing	May. 14	MT
Ginkgo Bioworks Holdings Insider Sold Shares Worth $1,606,162, According to a Recent SEC Filing	May. 14	MT
Ginkgo Bioworks Gets NYSE Noncompliance Notice on Minimum Closing Price	May. 13	MT
William Blair Downgrades Ginkgo Bioworks Holdings to Underperform From Market Perform	May. 10	MT
Ginkgo Bioworks Holdings Q1 Loss Narrows, Revenue Drops; 2024 Revenue Outlook Slashed; Cost Cuts Planned	May. 09	MT
Ginkgo Bioworks Holdings, Inc. Updates Revenue Guidance for the Full Year 2024	May. 09	CI
Transcript : Ginkgo Bioworks Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024	May. 09
Earnings Flash (DNA) GINKGO BIOWORKS Posts Q1 Revenue $38M, vs. Street Est of $46M	May. 09	MT
Ginkgo Bioworks Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Ginkgo Bioworks, GreenLab Launch Partnership to Produce Sugar Substitute Brazzein	May. 07	MT
GreenLab and Ginkgo Bioworks Announce New Partnership	May. 07	CI
Il Granaio delle Idee and Ginkgo Bioworks Announces Strategic Collaboration to Optimize Sourdough Strains for Bakery Products	Apr. 16	CI
Transcript : Ginkgo Bioworks Holdings, Inc. Presents at Ginkgo's Annual Ferment Conference 2024, Apr-11-2024	Apr. 11
Ginkgo Bioworks Acquires AgBiome's Platform Assets	Apr. 11	MT
Ginkgo Bioworks Expands Research Partnership With Novo Nordisk	Apr. 10	MT
Ginkgo Bioworks Partners With IdeeLab Biotechnology in Brazil	Apr. 08	MT
IdeeLab Joins the Ginkgo Technology Network to Provide Agriculture Companies in Brazil with End-to-End Product Development & Manufacturing Service	Apr. 08	CI
Ginkgo Bioworks, Prozomix Collaborate on Enzyme Development	Apr. 03	MT
Prozomix and Ginkgo Bioworks Collaborate on Next-Gen Enzyme Development for Sustainable API Manufacturing	Apr. 03	CI
Ginkgo Bioworks (NYSE: DNA) completed the acquisition of cell therapy platform assets of Modulus Therapeutics.	Apr. 01	CI
Ginkgo Bioworks Awarded $6 Million DARPA Contract to Work on Cold-Weather Applications for Military and Commercial Use	Mar. 28	MT
Ginkgo Bioworks Wins DARPA Funding to Produce Novel Proteins to Control Ice in Extreme Cold Weather Environments	Mar. 28	CI

Chart Ginkgo Bioworks Holdings, Inc.

Duration

Period

More charts

Company Profile

Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatic testing products and services primarily provided to public health authorities. It also focuses on the design of next-generation cell therapies for autoimmune diseases. It uses its platform to develop and screen libraries of novel NK-specific and T-cell specific chimeric antigen receptor and switch receptor designs, which enable control and performance of immune cell-based therapies.

Sector

Biotechnology & Medical Research

Calendar

2024-05-30 - Leerink Partners Healthcare Crossroads Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Ginkgo Bioworks Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.701 USD

Average target price

1.62 USD

Spread / Average Target

+131.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GINKGO BIOWORKS HOLDINGS, INC.	-58.52%	1.55B
MODERNA, INC.	+64.23%	62.59B
IQVIA HOLDINGS INC.	-2.31%	41.18B
LONZA GROUP AG	+44.36%	40.29B
CELLTRION, INC.	-8.29%	27.9B
ICON PUBLIC LIMITED COMPANY	+11.97%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.16%	19.09B
BIO-TECHNE CORPORATION	+7.54%	13.08B
MEDPACE HOLDINGS, INC.	+27.17%	12.05B
UNITED THERAPEUTICS CORPORATION	+25.72%	12.26B

Other Biotechnology & Medical Research